Description

Etamzilat (etamsylate) tablets 0.25 №50

Ingredients

Etamzilat (etamsylate) tablets contain 0.25mg of the active ingredient etamsylate. Other inactive ingredients may include fillers and binders.

Dosage

The recommended dosage of Etamzilat tablets is determined by a healthcare provider based on the individual’s condition. Generally, the usual dose is one tablet taken orally three times a day.

Indications

Etamzilat tablets are indicated for the treatment of various bleeding disorders, including menorrhagia, epistaxis, and bleeding associated with minor surgical procedures.

Contraindications

Do not use Etamzilat tablets if you are allergic to etamsylate or any other ingredients in the formulation. It is important to consult a healthcare professional before starting this medication.

Directions

Take Etamzilat tablets exactly as prescribed by your doctor. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.

Scientific Evidence

Etamsylate, the active ingredient in Etamzilat tablets, has been extensively studied for its hemostatic properties. Research has shown that etamsylate helps in the formation of blood clots by increasing platelet adhesiveness and reducing capillary permeability (Source: Journal of Hematology & Transfusion). Clinical trials have demonstrated the efficacy of etamsylate in various bleeding disorders, supporting its use in medical practice.

Additional Information

Etamzilat tablets have shown promising results in the management of bleeding disorders due to their hemostatic effects. The medication is well-tolerated by most patients with minimal side effects. It is important to follow the prescribed dosage and consult a healthcare provider for any concerns regarding the use of Etamzilat tablets.

Pharmacological Effects: Etamsylate works by stabilizing blood vessels and increasing platelet adhesiveness, leading to improved clot formation. This mechanism helps in controlling bleeding episodes effectively.

Clinical Trials: A randomized controlled trial published in the Journal of Hematology & Transfusion compared the efficacy of etamsylate with placebo in patients with menorrhagia. The study demonstrated a significant reduction in bleeding episodes and improvement in hemostatic parameters in the group treated with etamsylate.